Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis.

Kapoor A, Ellis A, Shaffer N, Gurwitz J, Chandramohan A, Saulino J, Ishak A, Okubanjo T, Michota F, Hylek E, Trikalinos TA.

J Thromb Haemost. 2017 Feb;15(2):284-294. doi: 10.1111/jth.13566. Epub 2017 Jan 19.

PMID:
28102615
2.

Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.

Venker BT, Ganti BR, Lin H, Lee ED, Nunley RM, Gage BF.

J Arthroplasty. 2017 Feb;32(2):645-652. doi: 10.1016/j.arth.2016.09.033. Epub 2016 Oct 5. Review.

PMID:
27823844
3.

Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis.

Dong WJ, Qian HJ, Qian Y, Zhou L, Hu SL.

Exp Ther Med. 2016 Aug;12(2):969-974. Epub 2016 May 18.

4.

Thromboprophylaxis and orthopaedic surgery: options and current guidelines.

Solayar GN, Shannon FJ.

Malays J Med Sci. 2014 May;21(3):71-7.

5.

Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.

Migita K, Bito S, Nakamura M, Miyata S, Saito M, Kakizaki H, Nakayama Y, Matsusita T, Furuichi I, Sasazaki Y, Tanaka T, Yoshida M, Kaneko H, Abe I, Mine T, Ihara K, Kuratsu S, Saisho K, Miyahara H, Segata T, Nakagawa Y, Kamei M, Torigoshi T, Motokawa S.

Arthritis Res Ther. 2014 Jul 21;16(4):R154. doi: 10.1186/ar4616.

6.

Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.

Alquwaizani M, Buckley L, Adams C, Fanikos J.

Curr Emerg Hosp Med Rep. 2013 Apr 21;1(2):83-97. Print 2013 Jun.

7.

Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry.

De Martino RR, Beck AW, Edwards MS, Corriere MA, Wallaert JB, Stone DH, Cronenwett JL, Goodney PP.

J Vasc Surg. 2012 Oct;56(4):1045-51.e1. doi: 10.1016/j.jvs.2012.02.066. Epub 2012 Jul 24.

8.

Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.

Donath L, Lützner J, Werth S, Kuhlisch E, Hartmann A, Günther KP, Weiss N, Beyer-Westendorf J.

Br J Clin Pharmacol. 2012 Dec;74(6):947-58. doi: 10.1111/j.1365-2125.2012.04302.x.

9.

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr; American College of Chest Physicians..

Chest. 2012 Feb;141(2 Suppl):e278S-325S. doi: 10.1378/chest.11-2404.

10.

New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty.

Friedman RJ.

Thrombosis. 2010;2010:280731. doi: 10.1155/2010/280731. Epub 2010 Jul 29.

11.

Spontaneous acute subdural hematoma due to fondaparinux: Report of two cases.

Fryburg K, Nguyen HS, Cohen-Gadol AA.

Surg Neurol Int. 2011;2:44. doi: 10.4103/2152-7806.79759. Epub 2011 Apr 19.

12.

Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism.

Fareed J, Adiguzel C, Thethi I.

Thromb J. 2011 Mar 28;9(1):5. doi: 10.1186/1477-9560-9-5.

13.

Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

Kapoor A, Chuang W, Radhakrishnan N, Smith KJ, Berlowitz D, Segal JB, Katz JN, Losina E.

Pharmacoeconomics. 2010;28(7):521-38. doi: 10.2165/11535210-000000000-00000. Review.

14.

Venous thromboembolic disease in colorectal patients.

McNally MP, Burns CJ.

Clin Colon Rectal Surg. 2009 Feb;22(1):34-40. doi: 10.1055/s-0029-1202884.

15.

Use of anticoagulants in elderly patients: practical recommendations.

Robert-Ebadi H, Le Gal G, Righini M.

Clin Interv Aging. 2009;4:165-77. Epub 2009 May 14. Review.

16.

Prospective monitoring improves outcomes of primary total hip replacement: a cohort study.

Streubel PN, Pachón M, Kerguelén CA, Navas J, Portocarrero J, Pesantez RF, Zayed G, Carrillo G, Llinás AM.

Patient Saf Surg. 2009 Apr 14;3(1):7. doi: 10.1186/1754-9493-3-7.

17.

Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.

Eriksson BI, Friedman RJ, Cushner FD, Lassen MR.

Clin Orthop Relat Res. 2008 Aug;466(8):2009-11; author reply 2012-4. doi: 10.1007/s11999-008-0324-2. Epub 2008 Jun 18. No abstract available.

18.

Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.

Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA.

Clin Orthop Relat Res. 2008 Mar;466(3):714-21. doi: 10.1007/s11999-007-0092-4. Epub 2008 Feb 10. Review.

19.
20.

Fondaparinux prevents venous thromboembolism after joint replacement surgery in Japanese patients.

Fuji T, Fujita S, Ochi T.

Int Orthop. 2008 Aug;32(4):443-51. Epub 2007 Apr 28.

Supplemental Content

Support Center